Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA/BLADDR 2020 | NMIBC: new approaches

Amir Mostafid • 9 Oct 2020
PROSCA/BLADDR 2020
Bladder Cancer Genitourinary Cancer

Amir Mostafid, MSc, FRCS, FEBU, Royal Surrey County Hospital, Guildford, Surrey, UK, discusses new approaches in treating non-muscle invasive bladder cancer (NMIBC) including en-bloc resection, genomics, gene sequencing, and improving urine-based biomarkers sensitivity for patients with low-risk NMIBC patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Amir Mostafid

4:01
NMIBC: relevance of prognostic markers
Amir Mostafid • 9 Oct 2020

Related Videos

10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals